# A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD)

> **NCT02092935** · PHASE2 · COMPLETED · sponsor: **Summit Therapeutics** · enrollment: 100 (actual)

## Conditions studied

- Clostridium Difficile Infection

## Interventions

- **DRUG:** SMT19969
- **DRUG:** Vancomycin

## Key facts

- **NCT ID:** NCT02092935
- **Lead sponsor:** Summit Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-04
- **Primary completion:** 2015-10
- **Final completion:** 2015-10
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2016-10-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02092935

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02092935, "A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02092935. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*